scholarly journals Assessment of the immunoexpression profile of breast ductal carcinoma with Cyclin D1, Her-2/Neu and p53 at Yangon General Hospital, Myanmar

2021 ◽  
Vol 5 (1) ◽  
pp. 44-49
Author(s):  
Khin Darli Tun ◽  
Min Ko Ko ◽  
Sudha Arumugam ◽  
Srikumar Chakravarthi ◽  
Jaya Vejayan
Keyword(s):  
Monoclonal Antibodies ◽  
Cyclin D1 ◽  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma ◽  
Histological Grade ◽  
Low Grade ◽  
High Grade ◽  
Carcinoma Of The Breast ◽  
Intermediate Grade ◽  
Ductal Carcinomas

One hundred cases of histologically proven invasive ductal carcinomas were histologically graded based on modified Bloom and Richardson Grading. Out of these 17 cases each of low grade, intermediate grade, and high grade invasive ductal carcinomas were selected for Immunostaining using the monoclonal antibodies Cyclin D1,pP53 and Her2/neu. It was found that for all three monoclonal antibodies the lowest histological grade of Invasive Ductal Carcinoma of the Breast showed the lowest positivity with Cyclin D1 ( 11.76%) and p53 ( 17.64%) and Her2/neu ( 47.05%). The intermediate grade tumour showed ( 70.58% ) positivity with Cyclin D1 and 58.58 % in p53 and Her2/neu. The high grade invasive ductal carcinoma of the breast showed the highest positivity of Cyclin D1 (76.47%) , p53 (88.24% ) ,Her2/neu ( 94.12% ); These suggest that Cyclin D1 , P53 and Her2/neuimmunoexpression positivity increases with rising histological grades of invasive ductal carcinoma of breast. 

Prognostic Significance of cyclin D1, β-catenin, and MTA1 in Patients with Invasive Ductal Carcinoma of the Breast

2012 ◽  
Vol 19 (13) ◽  
pp. 4129-4139 ◽  
Author(s):  
Chun-Wen Cheng ◽  
Yu-Fan Liu ◽  
Jyh-Cherng Yu ◽  
Hsiao-Wei Wang ◽  
Shian-Ling Ding ◽  
...  
Keyword(s):  
Cyclin D1 ◽  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma ◽  
Prognostic Significance ◽  
Carcinoma Of The Breast

scholarly journals Calretinin expression in high-grade invasive ductal carcinoma of the breast is associated with basal-like subtype and unfavorable prognosis

2013 ◽  
Vol 44 (12) ◽  
pp. 2743-2750 ◽  
Author(s):  
Ross J. Taliano ◽  
Shaolei Lu ◽  
Kamaljeet Singh ◽  
Shamlal Mangray ◽  
Rose Tavares ◽  
...  
Keyword(s):  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma ◽  
High Grade ◽  
Carcinoma Of The Breast

scholarly journals Imaging features of adenosquamous carcinoma of the breast – A rare variant of metaplastic breast carcinoma

2021 ◽  
pp. 20210108
Author(s):  
Tiffany Marian Sae-Kho ◽  
Asha Bhatt ◽  
Malvika H. Solanki ◽  
Elizabeth B. Jeans ◽  
Kimberly S. Corbin ◽  
...  
Keyword(s):  
Adenosquamous Carcinoma ◽  
Ductal Carcinoma ◽  
Case Series ◽  
Screening Mammography ◽  
Metaplastic Carcinoma ◽  
Whole Body ◽  
Low Grade ◽  
Imaging Features ◽  
High Grade ◽  
Carcinoma Of The Breast

Adenosquamous carcinoma of the breast is a rare subtype of metaplastic carcinoma, which accounts for <1% of invasive breast malignancy. Metaplastic carcinoma is usually high grade and aggressive with typically reported benign imaging features when compared to invasive ductal carcinoma. However, the adenosquamous variant is a subtype with a more favorable prognosis. Within the literature, there is limited imaging description with case studies focusing on metaplastic carcinoma. Herein, we report seven cases of the adenosquamous subtype describing the imaging findings with correlation to clinical history and pathology. The majority of patients (n = 6) presented with palpable breast masses. One patient was identified through screening mammography. Mammographically (n = 6), tumors appeared as irregular masses. Sonographically (n = 7), tumors appeared as irregular masses ranging from solid to mixed solid/cystic masses. On MRI (n = 1), one tumor appeared as an irregular rim enhancing mass. FDG PET/CT (n = 2) and whole-body bone scan (n = 1) were also available for review. The majority of tumors were low-grade (n = 6) with only one high-grade tumor. This case series of seven patients demonstrated predominantly suspicious imaging features despite the majority being low-grade tumors.

Distinguishing medullary carcinoma of the breast from high-grade hormone receptor-negative invasive ductal carcinoma: an immunohistochemical approach

2010 ◽  
Vol 56 (7) ◽  
pp. 852-859 ◽  
Author(s):  
Uta Flucke ◽  
Maria Theresia Flucke ◽  
Ludwig Hoy ◽  
Elisabeth Breuer ◽  
Rolf Goebbels ◽  
...  
Keyword(s):  
Invasive Ductal Carcinoma ◽  
Hormone Receptor ◽  
Ductal Carcinoma ◽  
Medullary Carcinoma ◽  
High Grade ◽  
Carcinoma Of The Breast

scholarly journals Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype

2012 ◽  
Vol 26 (4) ◽  
pp. 485-495 ◽  
Author(s):  
Shaolei Lu ◽  
Kamaljeet Singh ◽  
Shamlal Mangray ◽  
Rose Tavares ◽  
Lelia Noble ◽  
...  
Keyword(s):  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma ◽  
Molecular Subtype ◽  
High Grade ◽  
Carcinoma Of The Breast

scholarly journals Matriptase and Survivin Expression Associated with Tumor Progression and Malignant Potential in Breast Cancer of Chinese Women: Tissue Microarray Analysis of Immunostaining Scores with Clinicopathological Parameters

2008 ◽  
Vol 24 (2) ◽  
pp. 89-99 ◽  
Author(s):  
Wen-Chiuan Tsai ◽  
Chi-Hong Chu ◽  
Cheng-Pin Yu ◽  
Lai-Fa Sheu ◽  
Ann Chen ◽  
...  
Keyword(s):  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma ◽  
Survivin Expression ◽  
Normal Breast ◽  
Clinicopathological Parameters ◽  
Low Grade ◽  
High Grade ◽  
Ductal Hyperplasia ◽  
Grade Ii ◽  
Grade Iii

Objective: The aim of this study was to examine the expression of matriptase and survivin in breast carcinoma and correlate with clinicopathological parameters.Methods: Immunohistochemical analysis of matriptase and survivin were performed in tissue microarray slides of 290 cases, including 11 normal breast tissue; 27 fibrocystic disease; 17 fibroadenoma; 6 atypical ductal hyperplasia; 39 ductal carcinoma in situ, low grade (DCIS, low grade); 39 ductal carcinoma in situ, high grade (DCIS, high grade); 27 invasive ductal carcinoma, grade I (IDC, grade I); 78 invasive ductal carcinoma, grade II (IDC, grade II); and 46 invasive ductal carcinoma, grade III (IDC, grade III).Results: The average immunostaining scores of matriptase were 44.1 in normal breast tissue, 52.7 in fibrocystic disease, 76.5 in fibroadenoma, 81.7 in atypical ductal hyperplasia, 133.7 in low-grade DCIS, and 155.8 in high-grade DCIS. Among 151 breast IDC cases, the average immunostaining scores of matriptase were 172.7 in grade I, 211.7 in grade II, and 221.2 in grade III. Additionally, the average immunostaining scores of surviving also correlate with tumor grades and stages.Conclusions: Higher expressions of matriptase and survivin correlate significantly with clinicopathological parameters in breast cancer and the malignant potential in premalignant lesions. In addition, higher survivin expression had poorer prognosis of breast IDC cases.

scholarly journals Added value of contrast-enhanced spectral mammogram in assessment of suspicious microcalcification and grading of DCIS

2021 ◽  
Vol 52 (1) ◽  
Author(s):  
Ola Magdy Mohamed Shetat ◽  
Amr Farouk Ibrahim Moustafa ◽  
Sara Zaitoon ◽  
Mohamed Ibrahim Ibrahim Fahim ◽  
Ghada Mohamed ◽  
...  
Keyword(s):  
Ductal Carcinoma ◽  
Benign Lesion ◽  
Added Value ◽  
Low Grade ◽  
High Grade ◽  
Intermediate Grade ◽  
Invasive Component ◽  
Contrast Enhanced ◽  
Invasive Carcinomas ◽  
Mass Enhancement

Abstract Background Breast microcalcifications are one of the most difficult mammographic findings to assess. The purpose of this study is to assess the ability of contrast-enhanced spectral mammography in the assessment of suspicious microcalcification and in predicting the grade of DCIS. Methods Three hundred and forty cases with suspicious microcalcification were reviewed in this study. We excluded 160 cases associated with masses. We enrolled 180 cases for analysis of suspicious microcalcification on mammograms with no underlying masses. We reviewed the microcalcification for their morphology, distribution, and associated pathological enhancement according to BI-RADS lexicon with pathology results reviewed and classified into benign and malignant which subdivided into low, intermediate, or high-grade DCIS or invasive carcinoma. Results Three hundred and forty cases with suspicious microcalcification were reviewed in this study. We excluded 160 cases associated with masses. Forty-five of 180 cases were benign, and 135/180 cases were malignant. Twenty-five of 135 cases were diagnosed as invasive breast carcinomas while 110/135 were ductal carcinoma in situ. From the latter, 110 patients with DCIS, 22/110 cases were low grade, 11/110 cases were intermediate grade, and 77/110 cases were high grade (44 with micro-invasion). A total of 25 invasive carcinomas showed pathological non-mass enhancement, 76/77 cases of high-grade DCIS, and 6/11 cases of intermediate-grade DCIS. No abnormal enhancement appeared with benign entities, low-grade DCIS, and 5/11 cases of intermediate DCIS. The diagnostic performance of CESM in anticipation of high grade in DCIS patients was sensitivity of 98%, specificity of 81.8%, and accuracy of 93.1%. CESM sensitivity, specificity, and accuracy in prediction of invasiveness or high-grade DCIS were 98.5%, 81.8%, and 87.5%, respectively. Conclusion CESM can provide a fundamental contribution in the evaluation of suspicious microcalcification as high-grade DCIS or invasive component can present by non-mass enhancement, but enhancement paucity is favorable to diagnose benign lesion or non-invasive/low-grade DCIS.

Sign in / Sign up

Export Citation Format

Share Document